BioSpace News Archive

Business

Genomic Biopharma and patient advocacy organization POIC e dintorni APS partner to offer whole genome sequencing to bring better treatments and cures to those living with gastrointestinal diseases

Genomic Biopharma Inc. has partnered with Associazione Poic e Dintorni APS to enable access to whole genome sequencing (WGS) and demonstrate the utility of genomic information to treat and cure the most severe disorders of gut motility.

December 12, 2022
·
3 min read
Business

Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary

Organon today announced that Kirke Weaver has been appointed General Counsel and Corporate Secretary, and will continue as a member of Organon’s executive leadership team, effective January 1, 2023.

December 12, 2022
·
3 min read
BioMidwest

Celcuity Closes $100 Million Private Placement

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, today announced the closing of its private placement, resulting in gross proceeds of approximately $100 million, before deducting placement agent fees and other expenses.

December 12, 2022
·
7 min read
Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank

Inventiva announced the receipt of the €25 million payment under the first tranche of the unsecured loan agreement executed with the European Investment Bank on May 16, 2022 with a maturity date of December 2026.

December 12, 2022
·
11 min read
BioMidwest

PRTT status update announcement.

Protect Pharmaceutical Corporation, Inc. informs, that the Share Exchange Agreement №1, signed on June 15, 2022 was not executed due to the insufficiency of legal instruments on the territory of the Republic of Belarus for conducting such transactions, and terminated on December 6, 2022.

December 12, 2022
·
1 min read
Policy

Medivir has completed a successful pre-IND meeting with the FDA

Medivir AB announced that the company has completed a pre-IND meeting with the US Food and Drug Administration and has received positive feedback on the development plan in preparation for an IND for its candidate drug fostroxacitabine bralpamide.

December 12, 2022
·
3 min read
Hemogenyx Pharmaceuticals PLC - HEMO-CAR-T First PQ Run Completed

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its first Process Qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells.

December 12, 2022
·
2 min read
Policy

IRRAS Receives US FDA 510(k) Clearance for its Next Generation IRRAflow Control Unit

IRRAS announced that it received regulatory clearance from the United States Food, Drug, and Administration to active all of the functionality on the next generation control unit for its flagship product, IRRAflow, the world’s first and only active fluid exchange system.

December 12, 2022
·
3 min read
Policy

Abcam plc: Update on AIM Delisting

Abcam plc, and, a global leader in the supply of life science research tools, provides a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM, as originally announced on 17 October 2022.

December 12, 2022
·
4 min read
Drug Development

Asieris Enrolled First Patient for its Phase II Clinical Study of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

Asieris Pharmaceuticals announced that the first patient enrolled in phase II clinical study of oral APL-1202 in combination with PD-1 inhibitor Tislelizumab as neoadjuvant therapy for muscular invasive bladder cancer.

December 12, 2022
·
3 min read